65th ASH Annual Meeting & Exposition: 703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies

Symposia: Cellular Immunotherapies: Basic and Translational Oral and Poster Abstracts
Oral

Research, Translational Research

Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)

Moderators:

Liora Michal Schultz, MD, and Tim Sauer, MD,

Disclosures:

No relevant conflicts of interest to declare.

10:30 AM

763

Targeted In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform

James I Andorko, PhD^*, Ronnie M Russell, PhD^*, Bruce C Schnepp, PhD^*, Ramesh Singh, PhD^*, Debasish Boral, PhD^*, Thomas O'Malley^*, Leticia Kuri-Cervantes, PhD^*, Muneeswara B Medi, B.Pharm, PhD^*, Timothy D Culp, PhD^* and Philip R Johnson, MD^*

Interius BioTherapeutics, Inc., Philadelphia, PA

10:45 AM

764

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, MD, MSc¹^*, Jessica Devenport¹^*, Alun J Carter, PhD¹^*, Karl Staser, MD, PhD¹^*, Michael P. Rettig, PhD¹, Miriam Y Kim, MD¹, Julie O'Neal, PhD¹^*, Julie K. Ritchey¹^*, Feng Gao, MD, PhD²^*, Garrett Rettig³^*, Rolf Turk³^*, Alexandra Wolfarth⁴^*, Byung Ha Lee, PhD⁴^*, Matthew L. Cooper, PhD⁵ and John F. DiPersio, MD, PhD¹

¹Washington University School of Medicine, Saint Louis, MO
²Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
³Integrated DNA Technologies, Coralville, IA
⁴NeoImmuneTech, Inc, Rockville, MD
⁵Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

11:00 AM

765

Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized Mice

Maura Parker, PhD^*, Justin Ulrich-Lewis, PhD^*, Weiliang Tang, PhD^*, Chris Nicolai, PhD^*, Kathryn Michels, PhD^*, Susana Hernandez^*, Don Parrilla^*, Sara Cooper, MSc^*, Anai Perez^*, Mollie McDonnell, PhD^*, Greyson Hamilton^*, Chang-Chih Wu, PhD^*, Seungjin Shin, PhD^*, Andrew M. Scharenberg, MD^*, Ryan P. Larson, PhD^*, Laurie Beitz, MD^* and Byoung Y. Ryu, PhD

Umoja Biopharma, Seattle, WA

11:15 AM

766

Bispecific CAR-iNKT Immunotherapy for High Risk MLL-Rearranged Acute Lymphoblastic Leukemia

Hongwei Ren, MD, PhD¹^*, Natalina Elliott, PhD²^*, Bryan Lye, M. Phil¹^*, Joe Cross, PhD²^*, Lucy Field²^*, Kanagaraju Ponnusamy, PhD, MSc, BSc³^*, Irene Roberts, MD^2,4, Christina Halsey, MD, PhD⁵, Thomas Arthur Milne⁶, Anindita Roy, MD, PhD^2,4 and Anastasios Karadimitris, MD, PhD³^*

¹Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
²Department of Paediatrics, University of Oxford, Oxford, United Kingdom
³Hugh & Josseline Langmuir Centre for Myeloma Research Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
⁴Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
⁵Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
⁶MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

11:30 AM

767

In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeted Lentiviral Vector

Karina Krotova, PhD¹^*, Gopal Naik Nenavath, PhD¹^*, Nandakumar Packiriswamy, PhD, DVM¹^*, Rianna Vandergaast, PhD¹^*, Melissa Moy, PhD¹^*, Christopher Ziegler¹^*, Miguel A Muñoz Alía, PhD²^*, Kah-Whye Peng, PhD³^* and Stephen Russell, MD, PhD²

¹Imanis Life Sciences, Rochester, MN
²Vyriad, Rochester, MN
³Mayo Clinic, Rochester, MN

11:45 AM

768

Modulation of the Btla-HVEM Axis to Enhance CAR T Cell Immunotherapy Against Cancer

Puneeth Guruprasad¹, Alberto Carturan, MD²^*, Yunlin Zhang, MS²^*, Kingsley Gideon Kumashie, PhD³^*, Ivan J Cohen, PhD²^*, Guido Ghilardi, MD²^*, Ki-Hyun Kim⁴^*, Jong-Seo Lee⁴^*, Yoon Lee⁴^*, Jong-Hoon Kim⁴^*, Junho Chung, MD, PhD⁴^*, Maksim Shestov²^*, Raymone Pajarillo, MS²^*, Jaryse Harris, MD⁵^*, Yong Gu Lee, PhD²^*, Michael Wang²^*, Hatcher Ballard, BS²^*, Aasha Gupta, BS²^*, Ositadimma Ugwuanyi, BS²^*, Seok Jae Hong²^*, Linhui Chen²^*, Luca Paruzzo, MD²^*, Shane Kammerman³^*, Ruchi P. Patel, MS², Olga Shestova, PhD²^*, Laura Vella, MD, PhD³^*, Stephen J. Schuster, MD^2,6,7, Jakub Svoboda, MD^6,7, Patrizia Porazzi, PhD²^* and Marco Ruella, MD^2,6,7

¹Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, North Wales, PA
²Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
³Children's Hospital of Philadelphia, Philadelphia, PA
⁴Biopharmaceutical Research Center, AbClon Inc., Seoul, Korea, Republic of (South)
⁵Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, PA
⁶Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
⁷Department of Medicine, Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

703A.O1.6 703. Cellular Immunotherapies: Basic and Translational: Exploring Novel Platforms for Next-Gen CAR-Based Therapies